648 related articles for article (PubMed ID: 10955797)
1. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutations in Barrett's epithelium and esophageal cancer.
Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
[TBL] [Abstract][Full Text] [Related]
5. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
[TBL] [Abstract][Full Text] [Related]
8. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study.
Sorsdahl K; Casson AG; Troster M; Van Meyel D; Inculet R; Chambers AF
Cancer Detect Prev; 1994; 18(3):179-85. PubMed ID: 8076380
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
[TBL] [Abstract][Full Text] [Related]
10. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
11. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
13. [Frequency and significance of APC gene mutations in malignant degeneration of Barrett esophagus].
Stöltzing O; Schneider PM; Becker K; Wegerer S; Siewert JR; Hölscher AH
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):485-9. PubMed ID: 14518303
[TBL] [Abstract][Full Text] [Related]
14. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
15. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
Chung SM; Kao J; Hyjek E; Chen YT
Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
[TBL] [Abstract][Full Text] [Related]
16. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
17. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
[TBL] [Abstract][Full Text] [Related]
18. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of p53 in Barrett's oesophagus.
Krishnadath KK; van Blankenstein M; Tilanus HW
Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus.
Miyazono F; Schneider PM; Metzger R; Warnecke-Eberz U; Baldus SE; Dienes HP; Aikou T; Hoelscher AH
Oncogene; 2002 May; 21(23):3780-3. PubMed ID: 12032845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
